Thymalin Protocol: Immune System Reset for Longevity
Thymalin is a thymus-derived peptide extract studied as a counter to thymic involution — the progressive shrinkage of the thymus driving immunosenescence. It is usually paired with Epithalon, and its human evidence comes from one research network.
Evidence strength
Level 3
Case-control study
Peer-reviewed refs
3
Reading time
11 min
Key Takeaways
- The thymus gland shrinks by approximately 75% between ages 20 and 60. Thymalin is proposed to counter this; reversal of thymic involution in people is not shown in the studies cited here.
- In a 6-8 year study of 266 older people, the Thymalin + Epithalamin combination was reported to cut mortality 2.5-fold versus controls (4.1-fold with annual courses for 6 years). The report comes from the group that developed the peptides and has not been independently repeated.
- Community protocol: 10mg/day subcutaneous for 10 days, twice yearly, often in the same window as Epithalon. The published abstracts of the human studies do not state a dose.
- Thymalin is contraindicated in autoimmune diseases and with immunosuppressive medications — it amplifies immune activity.
The Thymus: The Organ Nobody Talks About
The immune system has a master training organ: the thymus. Located in the chest behind the sternum, it is where T-lymphocyte precursors from bone marrow travel to mature into functional immune cells. It is the organ that teaches T-cells to distinguish self from non-self — the fundamental capacity that prevents both infection and autoimmunity.
The thymus's central importance makes what happens to it with age all the more consequential. Starting around puberty, the thymus begins a process of involution — progressive replacement of functional thymic tissue with fat. By age 40, the thymus has lost approximately 50% of its original mass. By age 60, that figure reaches 75%.
The result is immunosenescence: reduced naive T-cell output, impaired vaccine response, increasing proportion of dysfunctional exhausted T-cells, and reduced cancer immunosurveillance. Many researchers now consider thymic involution a primary driver of age-related disease burden.
The Two-System Theory
The central hypothesis of the St. Petersburg group that developed both peptides proposes that biological ageing is governed by two master regulatory systems:
- The neuroendocrine system — regulated by the pineal gland (targeted by Epithalon)
- The immune system — regulated by the thymus (targeted by Thymalin)
The practical implication: treating only one system leaves the other in an aged state, limiting the benefit. The combination of Epithalon + Thymalin simultaneously addresses both master systems — the cohort study tested each peptide alone and the two together.
[1]The 266-Person Mortality Study
The most significant clinical evidence involves 266 elderly and older people followed for 6-8 years, with the peptides given during the first 2-3 years. Reported mortality fell 2.0-2.1-fold with Thymalin, 1.6-1.8-fold with Epithalamin, and 2.5-fold with the two combined versus controls. In a separate group given both peptides annually for 6 years, mortality was reported 4.1-fold lower.
This is extraordinary data. For context: most pharmaceutical interventions in elderly populations are considered significant if they produce a 20-30% mortality reduction. Alongside the mortality figures, the authors reported a 2.0-2.4-fold drop in acute respiratory illness and fewer clinical manifestations of ischaemic heart disease, hypertension and osteoporosis.
The caveats: the effect sizes are far larger than anything seen in comparable geroprotection research, and the report comes from a single group. The Oxford Level is therefore 3, not 1. The research was conducted by the same group that developed the compounds. Independent replication would substantially strengthen the evidence base.
[1]The combined thymalin and epithalon course, graded to this evidence and with monitoring and stop rules, is laid out in The Bio-Clock Reset Protocol.
Mechanism of Action
Thymopoiesis restoration: Thymalin stimulates the proliferation and maturation of T-cell precursors in the thymic cortex, increasing the output of naive T-cells into peripheral circulation.
T-cell subset normalisation: Restores the CD4+/CD8+ ratio, which becomes dysregulated with age (too many exhausted memory cells, too few naive cells capable of responding to new antigens).
Cytokine regulation: Normalises the production of thymic hormones (thymosin, thymulin, thymopoetin) that regulate T-cell maturation throughout the body.
Thymic activity: In rats, low-dose Thymalin increased lymphoproliferative activity and the content of tissue basophils and plasmocytes in the thymic lobules, alongside an antitumour effect in a transplanted sarcoma model.
[3]The Protocol
Synchronise with Epithalon cycles:
| Day | Epithalon | Thymalin |
|---|---|---|
| Days 1-10 | 10mg SC daily | 10mg SC daily |
| Days 11+ | Rest | Rest |
This is the community convention, not a trial dose: the published abstracts of the human studies do not state one. Running both peptides in the same window also means a side effect cannot be attributed to either; The Bio-Clock Reset Protocol explains why separate windows are the safer design.
Both peptides are injected subcutaneously each morning during the 10-day cycle. Most practitioners rotate between left and right lower abdominal quadrants.
Annual schedule: Two cycles per year — spring (March-April) and autumn (September-October). This timing is a community convention.
Monitoring: Consider tracking immune function markers before and after cycles: complete blood count with differential, NK cell activity (if accessible), and inflammatory markers (hs-CRP, IL-6).
Scientific References
- [1]Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life — Neuro Endocrinology Letters (2003)Oxford 2bPMID 14523363
- [2]Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results (in Russian) — Advances in Gerontology (2013)Oxford 4PMID 24003726
- [3]Zhukova GV, Schikhlyarova AI, Barteneva TA, et al.. Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo — Bulletin of Experimental Biology and Medicine (2018)Oxford 5PMID 29797130
Follow us on Google Search
Add BiohackingHub as a preferred source to see more of our research in Google results.
Related protocols
Partner with BiohackingHub
Editorial placements, sponsorships, and product features for evidence-minded brands.